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Abstract
Background and purpose: Chronic inflammatory demyelinating polyradiculoneuropathy 
(CIDP) is a clinical and electrophysiological heterogeneous immune- mediated polyneu-
ropathy. Intravenous immunoglobulin (IVIg), corticosteroids, and plasma exchange are 
proven effective treatments for CIDP. The clinical response to IVIg is variable between 
patients and currently unexplained. Finding biomarkers related to treatment response 
can help to understand the diversity of CIDP and personalise treatment choice.
Methods: We investigated whether genetic variation between patients may explain some 
of these differences in treatment response. Based on previous publications, we selected 
six candidate genes that might affect immune and axonal functions, IVIg metabolism, and 
treatment response in CIDP. Genetic variants were assessed in 172 CIDP patients treated 
with at least one course of IVIg (2 g/kg). A response to IVIg was defined by ≥1 grade 
improvement on the modified Rankin Scale. Blood samples were tested for variations in 
CNTN2, PRF1, FCGRT, FCGR2B, GJB1, and SH2D2A genes.
Results: In univariate analysis, patients with the FCGR2B promoter variant 2B.4/2B.1 re-
sponded more often to IVIg than patients with the 2B.1/2B.1 variant (odds ratio [OR] = 
6.9, 95% confidence interval [CI] = 1.6– 30; p = 0.003). Patients with the p.(Ala91Val) vari-
ant of PRF1 were less often IVIg responsive (OR = 0.34, 95% CI = 0.13– 0.91; p = 0.038). In 
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INTRODUC TION
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) 
is an immune- mediated disorder leading to limb muscle weakness, 
often with sensory disturbances. The majority of patients develop 
moderate to severe and disabling symptoms that require treatment 
[1]. Intravenous immunoglobulin (IVIg), corticosteroids, and plasma 
exchange have all been proven to be effective in CIDP [2]. Due to 
its rapid onset of action and lower occurrence of side effects, IVIg 
is often the first- choice treatment [3]. Most patients however, need 
long- term maintenance treatment with IVIg to maintain a stable clin-
ical condition and to prevent (secondary) axonal nerve damage [2]. 
The required dosage, interval, and duration of IVIg treatment differ 
between patients [4].
It is not known exactly how IVIg works, why there is a large vari-
ation in the required IVIg dosage, and why IVIg is not effective in ap-
proximately one quarter of CIDP patients [3,4]. Accurate biomarkers 
are urgently needed to predict the response to treatment and to adjust 
the required treatment dose [5,6]. This may help clinicians in choosing 
the most effective treatment for a specific patient at the onset of the 
disease. Early initiation of the optimal treatment may prevent unnec-
essary exposure to expensive or ineffective treatment [4,7].
There are several possible explanations for why IVIg is not ef-
fective in a subset of patients with CIDP. First, patients may be 
incorrectly diagnosed. Several disease mimics can be difficult to dis-
tinguish from CIDP, such as paraprotein- related polyneuropathy and 
Charcot– Marie– Tooth (CMT) disease [8,9]. A common genetic CIDP 
mimic caused by changes in the GJB1 gene is X- linked CMT disease 
with nonuniform nerve conduction slowing and dispersion suggest-
ing nonhereditary demyelination [8,10]. Second, patients may have 
predominant axonal damage, making the disease less responsive to 
IVIg [7]. Axonal dysfunction may arise from disturbed axoglial inter-
actions at the paranodes or juxtaparanodes [11]. Genetic variations 
in contactin 2 (CNTN2, also known as transient axonal glycoprotein 
1), a cell- adhesion molecule expressed in the juxtaparanode, have 
been linked to IVIg responsiveness [11]. Axonal damage may also 
be related to perforin 1 (PRF1) gene variations, which are described 
more often in patients with CIDP [7,12]. Perforin 1 is important for 
effector functions of natural killer (NK) cells and cytotoxic T cells. 
Cytotoxic T cells are clonally expanded in blood and peripheral 
nerves of patients with CIDP [13,14]. The apparent link between 
axonal damage, IVIg response, and T or NK cell function in CIDP 
may suggest that SH2D2A is another candidate genetic biomarker. 
SH2D2A encodes for T- cell- specific adaptor protein, and SH2D2A 
variants are reported to be more common in CIDP [15]. A third po-
tential explanation for IVIg unresponsiveness in some patients is 
variations in genes that affect IVIg metabolism. The pharmacokinet-
ics of IVIg differs considerably between CIDP patients, independent 
of the IVIg dose and interval [16]. Variation in FCGRT, coding for the 
neonatal Fc receptor that protects IgG from degradation, might in-
fluence IVIg clearance and its response [11,17– 19]. Last, the effect 
of IVIg may depend on the functioning of the Fc receptor FcγRIIb, 
which is an inhibitory receptor and a known target of IVIg. Changes 
in the gene coding for FcγRIIb (FCGR2B), linked to the development 
of autoimmune disorders such as CIDP, have been associated with 
IVIg response in Kawasaki disease [20,21]. Genetic variations may 
explain differences in IVIg treatment response. Because large un-
biased genome- wide association studies are challenging in a rare 
disease such as CIDP, we performed a candidate gene approach. 
We investigated genetic variation in GJB1, CNTN2, PRF1, SH2D2A, 
FCGRT, and FCGR2B in a group of CIDP patients in relation to their 
IVIg response. Finding biomarkers that are associated with the re-
sponse to IVIg may help us to improve our understanding of the 
therapeutic heterogeneity in CIDP and may lead to more person-
alised treatment regimens for patients with CIDP.
MATERIAL S AND METHODS
Patients and treatment
Data were collected retrospectively from clinical trials or medical 
files from CIDP patients who were diagnosed and treated at the 
Erasmus MC University Medical Centre between 1980 and 2018. 
Part of the cohort was described previously [4,22]. Patients fulfilled 
the European Federation of Neurological Societies/Peripheral Nerve 
Society clinical criteria for typical and atypical CIDP [3]. Patients 
with an IgM monoclonal gammopathy with anti- myelin- associated 
glycoprotein antibodies were excluded. All included patients were 
treated with at least one full course of IVIg (2 g/kg). Improvement 
after initial IVIg treatment was defined by a clinical improvement of 
at least one grade on the modified Rankin Scale [23]. Patients were 
only included when the response to IVIg could be determined by a 
neuromuscular expert (P.A.v.D., B.C.J., and K.K.) and when a blood 
multivariate analysis, both PRF1 and FCGR2B showed discriminative ability to predict the 
chance of IVIg response (area under the curve = 0.67).
Conclusions: Variations in PRF1 and the promoter region of FCGR2B are associated with 
the response to IVIg in CIDP. These findings, which require validation, are a first step to-
wards the understanding of the heterogeneity in the treatment response in CIDP.
K E Y W O R D S
chronic inflammatory demyelinating polyradiculoneuropathy, genetic variation, intravenous 
immunoglobulin
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sample was available for DNA extraction. This study was approved 
by the medical ethical committee of the Erasmus MC University 
Medical Centre in Rotterdam (MEC- 2016– 624).
Genetic analysis
Genomic DNA was isolated from peripheral blood in EDTA antico-
agulated tubes using standard methods. The following candidate 
genes were investigated: CNTN2, PRF1, FCGRT, SH2D2A, FCGR2B, 
and GJB1.
CNTN2 and PRF1
CNTN2 (NM_005076.3:c.443G>A p.[Ala145 Thr]; rs2275697) and 
PRF1 (NC_000010.10:g.72360387G>A p.[Ala91Val]; rs35947132) 
genotypes were determined by quantitative polymerase chain 
reaction (PCR) using fluorescently labelled primer/probe sets 
from Applied Biosystems. Sanger sequencing was used to vali-
date the test using the following primers for CNTN2 and PRF1, re-
spectively: 5’- TTTGGGGGAGGGGGAGAG- 3’ (forward), 5’- AGGC 
GGAAGCAGGGCACA- 3’ (reverse) and 5’- CAGCCGCACGCTCAGA 
GTG- 3’ (forward), 5’- ACCCCTAGCCCCAGCTCTCAC- 3’ (reverse).
FCGRT and SH2D2A
The variable number of tandem repeats ranging from one to five 
in the promoter region of the FCGRT gene (currently reported as 
deletion– insertion at location g.49512975 of reference sequence 
NC_000019.10; rs746313390) was determined by PCR amplifi-
cation followed by agarose gel electrophoresis as described be-
fore [24]. For SH2D2A (NC_000001.10:g.156786867GA[10_24]), 
200 ng of DNA was added to a master mix containing PCR gold 
buffer (Applied Biosystems), dNTP (20 mM), MgCl2 (25 mM), 
primers, and Taq gold polymerase. Primer sequences were as fol-
lows: 5'- CTGCCCCCTCCCTTCCTCAT- 3' (forward) and 5'- (6- FAM) 
TGCCCCCTCACCCCAAA- 3' (reverse). The PCR program consisted 
of 40 cycles of 95°C for denaturation, 60°C for annealing, 72°C 
for elongation, and 15°C for the final hold. Subsequently product 
lengths were determined using Gene Scan analysis. The length of 
the GA repeat in the promoter area of the SH2D2A gene is bimodally 
distributed; therefore, a GA repeat of ≤16 was designated as "short" 
and a GA repeat of >16 was designated as "long" [25].
FCGR2B
Genetic variations in the 2- kb promoter region of FCGR2B 
(NM_004001.4:c.- 386G>C; rs143796418 and NM_004001.4:c.- 
120 T > A; rs780467580) of the FCGR2B gene and in the transmem-
brane region (NM_004001.4:c.695 T > C p.[Ile232 Thr], rs1050501) 
were determined by multiplex ligation- dependent probe amplifica-
tion (MLPA). The FCGR2B promoter variant alleles were defined as 
2B.1 (c.[−386G;- 120 T]), 2B.2 (c.[−386C;- 120 T]), or 2B.4 (c.[−386C;- 
120A]). The combination c.[−386G;- 120A] has never been reported 
in FCGR2B. The MLPA procedure was carried out as previously de-
scribed [26,27].
GJB1
The promoter (P1 and P2) and coding region of the GJB1 gene was 
sequenced using routine clinical genetic diagnostic methods. Primer 
sequences are available upon request.
Statistical analysis
Chi- squared tests, chi- squared tests for trend, or Fisher exact tests 
were used to compare the response to IVIg between patients with dif-
ferent clinical characteristics as well as in patients with different genetic 
variants. Age at start of IVIg treatment was compared between patients 
who responded and did not respond to IVIg as well as in patients with 
different genetic variants using unpaired t- test or one- way analysis of 
variance. A two- tailed p- value < 0.05 was considered statistically sig-
nificant. To verify whether the genotype frequencies were in Hardy– 
Weinberg equilibrium, the method of Ott was used. We modelled the 
odds of responding to IVIg using a multivariate logistic regression model. 
To prevent overfitting and minimise prediction error, we used regulari-
sation employing the least absolute shrinkage and selection operator 
(LASSO) method [28]. Regularisation is a statistical technique that is 
often applied in machine learning prediction modelling. To prevent a 
large number of coefficients relative to the size of the dataset leading to 
large variability of estimates and large errors, the LASSO method places 
a penalty on the absolute size of the coefficients in the likelihood func-
tion. As an added benefit, the method will also lead to more interpreta-
ble models, because the LASSO method usually sets some coefficients 
to zero, thereby selecting the most informative variables for the model. 
Cross- validation was used to find the optimal penalty factor [28]. Model 
performance was quantified with respect to discrimination by the area 
under the receiver operating curve (AUC). The AUC ranges from 0.5 to 
1.0 for sensible models [29]. Statistical analysis was conducted using 
SPSS Statistics for Windows, version 24 (IBM; 2016) and R: A Language 
and Environment for Statistical Computing, version 3.5.1 (R Foundation 
for Statistical Computing; 2018).
RESULTS
Patient cohort
In total, 172 CIDP patients were included. Of these 172 patients, 
65% were male. The median age of IVIg commencement was 
55 years (range = 2– 90), and the overall response rate to IVIg was 
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79% (n = 136). In this cohort 66% of the patients who improved after 
IVIg were male and 67% of the patients who did not improve after 
IVIg were male (p = 1.0). The percentage of acute onset CIDP was no 
different in the group of patients who improved after IVIg compared 
to the patients who did not improve (40% vs. 36%, p = 0.69). The age 
of patients when IVIg treatment was started was not different in pa-
tients who responded compared to patients who were unresponsive 
to IVIg (mean = 51 years vs. 55 years, p = 0.50). Clinical characteris-
tics in different genotype subgroups are listed in Tables S1 and S2.
Genetic association studies
We were able to determine CNTN2, PRF1, and FCGR2B genotypes in 
all 172 patients. FCGRT and SH2D2A genotypes were defined suc-
cessfully in 163 and 166 patients, respectively. All genotypes were 
in Hardy– Weinberg equilibrium. From 169 patients, enough DNA 
was available to test for GJB1. No disease- associated changes were 
observed in the GJB1 gene in any of the 169 samples.
The response to IVIg in relation to the different genotypes is 
shown in Table 1. In univariate analysis, patients with the heterozy-
gous p.(Ala91Val) variant of PRF1 were less likely to be IVIg respon-
sive (odds ratio [OR] = 0.34, 95% confidence interval [CI] = 0.13– 0.91; 
p = 0.038). Patients with the 2B.4/2B.1 variant of FCGR2B were 
more likely to be responsive to IVIg than patients with the 2B.1/2B.1 
variant (OR = 6.9, 95% CI = 1.6– 30; p = 0.003). To analyse the con-
tribution of all genotypes, we performed multivariate logistic regres-
sion using the LASSO penalty. Patients with missing genotype data 
for FCGRT or SH2D2A could not be included in the multivariate anal-
ysis; furthermore, the rare variants that only occurred in one patient 
were left out of this multivariate analysis. In the resulting multivar-
iate LASSO logistic regression (Table 2; n = 157), the PRF1 p.(Ala-
91Val) variant was negatively associated with the IVIg response (OR 
= 0.57), whereas the FCGR2B promoter 2B.4/2B.1 variant was pos-
itively associated with a response (OR = 2.56). All other covariates 
were shrunken towards zero. Together, PRF1 and FCGR2B promoter 
variants showed discriminative ability (AUC = 0.67) in predicting the 
chance of IVIg response. Clinical characteristics such as gender, age 
at start of IVIg treatment, and disease course (acute onset) did not 
differ in genotype subgroups (Tables S1 and S2).
DISCUSSION
We determined that genetic variations in PRF1 and the promoter re-
gion of FCGR2B are associated with the response to IVIg in CIDP. The 
p.(Ala91Val) variant of PRF1 was negatively associated, whereas the 
FCGR2B promoter 2B.4/2B.1 variant was positively associated with 
a response to IVIg. Variations in CNTN2, FCGRT, and SH2D2A were 
not associated with IVIg response.
Perforin is important for cytotoxic functions of T cells, NK cells, 
and NK T cells [12]. Both cytotoxic T cells and NK T cells were re-
cently reported to be elevated in the cerebrospinal fluid of CIDP 
patients [30]. The variant p.Ala91Val is known to reduce the cyto-
toxic activity of perforin due to protein misfolding [31]. We found 
that CIDP patients with the p.(Ala91Val) PRF1 variant were less 
responsive to IVIg. PRF1 genetic variants are reported to be more 
prevalent in CIDP patients with axonal damage, suggesting a possi-
ble association with treatment response [12]. Axonal nerve damage, 
usually reflected by muscle atrophy and a reduced compound muscle 
action potential, has been associated with a poor response to IVIg in 
CIDP [7,11,32]. Although no systematic electrodiagnostic data were 
available in our cohort, axonal damage might explain the lack of IVIg 
response we found in patients carrying the PRF1 variant. Whether 
the axonal damage itself or the variation in PRF1 causes the lack of 
TA B L E  1  IVIg response in chronic inflammatory demyelinating 
polyradiculoneuropathy patients with different genetic variations
Genotype
Unresponsive 
to IVIg, n (%)
Responsive to 
IVIg, n (%) p
Total 36 (21%) 136 (79%)
PRF1 p.(Ala91Val), n = 172
Ala/Ala 28 (18%) 124 (82%)
Ala/Val 8 (40%) 12 (60%) 0.038a
CNTN2 p.(Ala145 Thr), n = 172
Ala/Ala 23 (19%) 98 (81%)
Ala/Thr 13 (27%) 35 (73%)
Thr/Thr 0 (0%) 3 (100%) NS
FCGRT VNTR, n = 163
2/2 0 (0%) 1 (100%)
3/2 5 (16%) 26 (84%)
3/3 29 (23%) 101 (78%)
3/5 0 (0%) 1 (100%) NS
FCGR2B promoter, n = 172
2B.1/2B.1 33 (26%) 95 (74%)
2B.4/2B.1 2 (5%) 40 (95%)
2B.4/2B.2 1 (100%) 0 (0%)
2B.4/2B.4 0 (0%) 1 (100%) 0.006a
FCGR2B p.(Ile232 Thr), n = 172
Ile/Ile 30 (21%) 111 (79%)
Ile/Thr 6 (20%) 24 (80%)
Thr/Thr 0 (0%) 1 (100%) NS
SH2D2A VNTR, n = 166
GA≤16/GA≤16, 
short/short
2 (13%) 14 (88%)
GA≤16/GA>16, 
short/long
15 (22%) 54 (78%)
GA>16/GA>16, 
long/long
18 (22%) 63 (78%) NS
Note:: To compare the response to IVIg between patients with different 
genetic variants, chi- squared tests, chi- squared tests for trend, or 
Fisher exact tests were used.
Abbreviations: IVIg, intravenous immunoglobulin; NS, not significant; 
VNTR, variable number of tandem repeats.
aStatistically significant.
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response needs further exploration. Furthermore, genetic variation 
in PRF1 was associated with a relapsing course suggesting a demy-
elinating form more responsive to IVIg [12]. The p.Ala91Val variant 
has been associated with several immune- mediated disorders such 
as multiple sclerosis and systemic onset juvenile idiopathic arthri-
tis, suggesting that PRF1 variants predispose to autoimmunity [33]. 
PRF1 variants are also reported more often in CIDP compared to 
healthy controls, but whether CIDP patients with p.Ala91Val PRF1 
represent a different subgroup in which dysfunction of cytotoxic T 
cells and NK T cells leads to nerve damage that is unresponsive to 
IVIg needs further exploration [12].
CIDP patients with the 2B.4/2B.1 promoter genotype for FCGR2B 
were more likely to be IVIg responsive. The FcγRIIb receptor is ex-
pressed by monocytes, macrophages, dendritic cells, and B cells and is 
a negative regulator of cellular activation, proliferation, and cytokine 
production [20]. FcγRIIb may contribute to the therapeutic action of 
IVIg, because disruption of the FcγRIIb pathway by genetic deletion or 
a blocking monoclonal antibody can reverse the therapeutic effects of 
IVIg in rodents [34]. However, it must be noted that the role of FcγRIIb 
is dependent on the mouse strain and IVIg dose [35]. Our findings 
support the concept that FcγRIIb is important for the therapeutic ac-
tion of IVIg in CIDP, as the 2B.4 variant has been reported to induce 
de novo expression of FcγRIIb on monocytes and neutrophils and may 
therefore lead to more effective inhibition by IVIg [27]. It is also pos-
sible that the 2B.4 haplotype promoter activity is higher than in the 
more common 2B.1 haplotype, resulting in increased expression [36]. 
Our data suggest that increased expression of FcγRIIb is beneficial 
to IVIg treatment in CIDP. The cell type responsible for the FcγRIIb- 
mediated beneficial effect of IVIg should be further investigated. In 
Kawasaki disease, another IVIg responsive immune- mediated disease, 
it was also shown that patients carrying the 2B.4 variant were more 
likely to be IVIg responsive [21]. Of note, the association between IVIg 
response and FCGR2C- ORF (data not shown), which is in linkage dis-
equilibrium with the 2B.4 promoter haplotype [26] was less strong 
(p = 0.05; data not shown), suggesting that FcγRIIb is more import-
ant in mediating the beneficial effect of IVIg than FcγRIIc. In addition, 
we could not find an association between FCGR2B p.(Ile232 Thr) and 
the response to IVIg in CIDP. Because FCGR2B p.(Ile232 Thr) is well 
known to impact signalling through FcγRIIb, our data suggest that 
the expression level or pattern of FcγRIIb, rather than its signalling 
strength, is important for IVIg efficacy [37]. In addition to its role in 
IVIg treatment response, FcγRIIb is likely to influence the suscepti-
bility to other autoimmune disorders and CIDP [20,38]. Although we 
did not compare the frequency of FCGR2B with healthy controls, it is 
notable that we found a lower percentage of the 2B.4/2B.1 genotype 
in CIDP than previous reports [20]. Similar to a study in Guillain– Barré 
syndrome patients, we were unable to find an association between 
IVIg efficacy and variation in FCGRT [24].
We could not confirm the association between CNTN2 varia-
tions and response to IVIg found in a Japanese group of patients, 
which may be explained by the different genetic background [11]. It 
is known that the allele frequency of CNTN2 p.Ala145 Thr is higher 
in Europe compared to Asia (1000 Genomes Browser, accessed 28 
August 2020, https://www.ncbi.nlm.nih.gov/varia tion/tools/ 1000g 
enome s/) [39].
We demonstrate that genetic variations in PRF1 and FCGR2B 
genes may partly explain the variability in IVIg response in CIDP pa-
tients. The rarity of the disease and overall good responsiveness to 
IVIg limits the chance of demonstrating an association between ge-
netic variants and treatment efficacy. Also, the frequency of some of 
the genetic variations was low. Furthermore, we used quite a strict 
cutoff value of at least one grade improvement on the modified 
Rankin Scale for IVIg response to ensure a clear and clinically relevant 
improvement. It would have been interesting to know not only the ini-
tial response to IVIg, but also the dose and frequency required during 
maintenance treatment. Currently, hardly any genetic association 
studies have been conducted in CIDP to explain the variation in treat-
ment response [11]. To our knowledge, this is the largest study inves-
tigating genetic variations in association with IVIg response in CIDP so 
far. Our study population seems representative of the general CIDP 
population regarding age, male predominance, and response rate to 
IVIg [2,4]. Moreover, the long follow- up of most patients improved the 
diagnostic certainty in our cohort, which is important because misdi-
agnosis of CIDP has been reported in a randomised controlled trial in 
58% of treatment- unresponsive patients [40]. Limitations of our study 
are its relatively small sample size for a genetic study, its retrospec-
tive nature, and that our patients were mainly of European descent. 
Furthermore, we were unable to measure each genetic variant in all 
patients. The association of PRF1 and FCGR2B promoter variants with 
the response to IVIg in CIDP found in our study needs replication in 
another study. The Dutch CIDP Outcome Study, an observational pro-
spective cohort study, and the international INCbase might be good 
platforms to validate our results on a larger scale and to study genetic 
variants related to treatment response in CIDP patients from different 
geographical areas [41]. In addition, these studies use other outcome 
scales that may detect more subtle changes in the severity of the dis-
ease course and outcome. Ultimately, these pharmacogenomic stud-
ies may lead to a more personalised therapeutic approach improving 
the clinical outcome of patients by selecting the optimal treatment 
type and regimen at an early disease stage.
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